{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Acute+Myeloid+Leukemia+%28AML%29&page=3", "query": { "condition": "Acute Myeloid Leukemia (AML)", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 2378, "total_pages": 238, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Acute+Myeloid+Leukemia+%28AML%29&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Acute+Myeloid+Leukemia+%28AML%29&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-10T01:44:55.638Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00502905", "title": "Busulfan and Fludarabine in Patients With AML and MDS", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "Busulfan", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "66 Years", "sex": "ALL", "summary": "Up to 66 Years" }, "enrollment_count": 200, "start_date": "2003-10", "completion_date": "2008-11", "has_results": true, "last_update_posted_date": "2012-05-28", "last_synced_at": "2026-10-10T01:44:55.638Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00502905" }, { "nct_id": "NCT00576979", "title": "Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "intensity-modulated radiation therapy", "type": "RADIATION" }, { "name": "tomotherapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "7 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "7 Years to 55 Years" }, "enrollment_count": 51, "start_date": "2008-03-04", "completion_date": "2026-01-07", "has_results": true, "last_update_posted_date": "2026-03-24", "last_synced_at": "2026-10-10T01:44:55.638Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00576979" }, { "nct_id": "NCT00315705", "title": "A Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Children With Acute Leukemias.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Acute Myelogenous Leukemia", "Relapsed Leukemia" ], "interventions": [ { "name": "clofarabine", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genzyme, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 50, "start_date": "2006-03", "completion_date": "2010-05", "has_results": true, "last_update_posted_date": "2014-04-14", "last_synced_at": "2026-10-10T01:44:55.638Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00315705" }, { "nct_id": "NCT00060372", "title": "Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative", "Childhood Myelodysplastic Syndromes", "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Disseminated Neuroblastoma", "Malignant Neoplasm", "Ovarian Choriocarcinoma", "Ovarian Embryonal Carcinoma", "Ovarian Immature Teratoma", "Ovarian Mature Teratoma", "Ovarian Mixed Germ Cell Tumor", "Ovarian Monodermal and Highly Specialized Teratoma", "Ovarian Polyembryoma", "Ovarian Yolk Sac Tumor", "Previously Treated Myelodysplastic Syndromes", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Malignant Testicular Germ Cell Tumor", "Recurrent Mantle Cell Lymphoma", "Recurrent Neuroblastoma", "Recurrent Ovarian Epithelial Cancer", "Recurrent Ovarian Germ Cell Tumor", "Refractory Chronic Lymphocytic Leukemia", "Refractory Multiple Myeloma", "Relapsing Chronic Myelogenous Leukemia", "Stage I Multiple Myeloma", "Stage II Multiple Myeloma", "Stage II Ovarian Epithelial Cancer", "Stage III Malignant Testicular Germ Cell Tumor", "Stage III Multiple Myeloma", "Stage III Ovarian Epithelial Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer", "Stage IV Ovarian Epithelial Cancer", "Testicular Choriocarcinoma", "Testicular Choriocarcinoma and Embryonal Carcinoma", "Testicular Choriocarcinoma and Seminoma", "Testicular Choriocarcinoma and Teratoma", "Testicular Choriocarcinoma and Yolk Sac Tumor", "Testicular Embryonal Carcinoma", "Testicular Embryonal Carcinoma and Seminoma", "Testicular Embryonal Carcinoma and Teratoma", "Testicular Embryonal Carcinoma and Teratoma With Seminoma", "Testicular Embryonal Carcinoma and Yolk Sac Tumor", "Testicular Embryonal Carcinoma and Yolk Sac Tumor With Seminoma", "Testicular Teratoma", "Testicular Yolk Sac Tumor", "Testicular Yolk Sac Tumor and Teratoma", "Testicular Yolk Sac Tumor and Teratoma With Seminoma" ], "interventions": [ { "name": "ipilimumab", "type": "DRUG" }, { "name": "therapeutic allogeneic lymphocytes", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2003-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-03-27", "last_synced_at": "2026-10-10T01:44:55.638Z", "location_count": 5, "location_summary": "La Jolla, California • Atlanta, Georgia • Boston, Massachusetts", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00060372" }, { "nct_id": "NCT01564277", "title": "Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Blastic Phase Chronic Myelogenous Leukemia", "Contiguous Stage II Adult Burkitt Lymphoma", "de Novo Myelodysplastic Syndromes", "Noncontiguous Stage II Adult Burkitt Lymphoma", "Previously Treated Myelodysplastic Syndromes", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Stage I Adult Burkitt Lymphoma", "Stage III Adult Burkitt Lymphoma", "Stage IV Adult Burkitt Lymphoma", "Untreated Adult Acute Lymphoblastic Leukemia", "Untreated Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "rasburicase", "type": "DRUG" }, { "name": "allopurinol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2011-09-29", "completion_date": "2016-05-28", "has_results": true, "last_update_posted_date": "2018-01-09", "last_synced_at": "2026-10-10T01:44:55.638Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01564277" }, { "nct_id": "NCT00003805", "title": "Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bone Marrow Suppression", "Fever, Sweats, and Hot Flashes", "Infection", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Unspecified Adult Solid Tumor, Protocol Specific", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "piperacillin sodium", "type": "DRUG" }, { "name": "piperacillin-tazobactam", "type": "DRUG" }, { "name": "tazobactam sodium", "type": "DRUG" }, { "name": "vancomycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "European Organisation for Research and Treatment of Cancer - EORTC", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 859, "start_date": "1997-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2012-09-24", "last_synced_at": "2026-10-10T01:44:55.638Z", "location_count": 2, "location_summary": "Baltimore, Maryland • Boston, Massachusetts", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003805" }, { "nct_id": "NCT06852222", "title": "A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Leukemia, Myeloid, Acute" ], "interventions": [ { "name": "Bleximenib", "type": "DRUG" }, { "name": "Venetoclax (VEN)", "type": "DRUG" }, { "name": "Azacitidine (AZA)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 600, "start_date": "2025-06-04", "completion_date": "2029-08-15", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-10T01:44:55.638Z", "location_count": 59, "location_summary": "Birmingham, Alabama • Goodyear, Arizona • Tucson, Arizona + 43 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06852222" }, { "nct_id": "NCT05146739", "title": "Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia Post Cytotoxic Therapy", "Myelodysplastic Syndrome Post Cytotoxic Therapy", "Myeloid Leukemia Associated With Down Syndrome", "Recurrent Acute Myeloid Leukemia", "Recurrent Mixed Phenotype Acute Leukemia", "Recurrent Myelodysplastic Syndrome", "Refractory Acute Myeloid Leukemia", "Refractory Mixed Phenotype Acute Leukemia", "Refractory Myelodysplastic Syndrome" ], "interventions": [ { "name": "Cytarabine", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Triple Intrathecal Chemotherapy", "type": "DRUG" }, { "name": "Uproleselan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "17 Years", "sex": "ALL", "summary": "Up to 17 Years" }, "enrollment_count": 8, "start_date": "2023-10-10", "completion_date": "2027-05-09", "has_results": true, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-10-10T01:44:55.638Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05146739" }, { "nct_id": "NCT01349972", "title": "Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome", "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)", "Adult Acute Monoblastic Leukemia (M5a)", "Adult Acute Monocytic Leukemia (M5b)", "Adult Acute Myeloblastic Leukemia With Maturation (M2)", "Adult Acute Myeloblastic Leukemia Without Maturation (M1)", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Acute Myelomonocytic Leukemia (M4)", "Adult Erythroleukemia (M6a)", "Adult Pure Erythroid Leukemia (M6b)", "Secondary Acute Myeloid Leukemia", "Untreated Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "alvocidib", "type": "DRUG" }, { "name": "daunorubicin hydrochloride", "type": "DRUG" }, { "name": "mitoxantrone hydrochloride", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 172, "start_date": "2011-04", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2017-07-31", "last_synced_at": "2026-10-10T01:44:55.638Z", "location_count": 11, "location_summary": "Scottsdale, Arizona • Tampa, Florida • Atlanta, Georgia + 7 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01349972" }, { "nct_id": "NCT02203773", "title": "Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myelogenous Leukemia", "Myelogenous Leukemia", "Treatment Naive AML" ], "interventions": [ { "name": "Posaconazole", "type": "DRUG" }, { "name": "ABT-199", "type": "DRUG" }, { "name": "Decitabine", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 212, "start_date": "2014-10-06", "completion_date": "2022-06-16", "has_results": false, "last_update_posted_date": "2023-05-16", "last_synced_at": "2026-10-10T01:44:55.638Z", "location_count": 13, "location_summary": "Duarte, California • Sacramento, California • Aurora, Colorado + 8 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02203773" } ] }